SCHEMBL4428290

SCHEMBL4428290

c1ccc(CCN(Cc2cccc(CNCc3ccccn3)c2)Cc2ccccn2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
TDP1 Q9NUW8 2/20 0.50
MAPT P10636 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
LIN28A Q9H9Z2 1/20 0.50
KDM4E B2RXH2 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.45
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1882890 0.83 ALDH1A1 (0.44) ALDH1A1MEN1KMT2ATDP1MAPT
SCHEMBL29823331 0.83 ALDH1A1 (0.44) ALDH1A1MEN1KMT2ATDP1MAPT
SCHEMBL14931741 0.81 KMT2A (0.68) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL30225577 0.81 KMT2A (0.68) ALDH1A1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL1875063 0.80 ALDH1A1 (0.47) ALDH1A1MEN1KMT2ATDP1MAPT
SCHEMBL30338237 0.80 ALDH1A1 (0.47) ALDH1A1MEN1KMT2ATDP1MAPT
SCHEMBL13016958 0.78 MAPT (0.63) KMT2ATDP1MAPTSMN1; SMN2LIN28A
SCHEMBL6781182 0.78 ALDH1A1 (0.45) ALDH1A1MEN1KMT2ATDP1MAPT
SCHEMBL3389096 0.77 CYP2D6 (0.61) ALDH1A1TDP1MAPTSMN1; SMN2LIN28A
SCHEMBL19211537 0.77 TDP1 (0.58) ALDH1A1MEN1KMT2ATDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2056853-A1 COMBINATION THERAPY Genzyme Corporation (US) 2009-05-13 EP disclosed
WO-2008019371-A1 COMBINATION THERAPY GENZYME CORPORATION (US) 2008-02-14 WO disclosed
US-6750348-B1 PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE ANORMED, INC. (CA) 2004-06-15 US disclosed